CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
CRISPR Therapeutics AG (CRSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results – CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. f
How this was made
The 30-second read
Why it matters
The combination of strong quarterly revenue and new FDA designations provides fresh positive catalysts that could move the stock.
Market read
First‑report of Q3 results and regulatory milestones makes this a high‑impact biotech news item.
What to watch
Potential regulatory delays in other regions and competition from rival gene‑editing platforms.
CASGEVY generated $99 million of third-quarter 2026 revenue, up 30% quarter-over-quarter, while CRISPR Therapeutics reported a $111.4 million net loss and ended the quarter with $2,276.6 million of cash, cash equivalents, and marketable securities.
CASGEVY commercial momentum and pipeline progress were offset by a wider year-over-year net loss, higher research and development expense, acquired in-process R&D expense, and the absence of financial guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| CASGEVY revenue, third quarter 2026other | $99M | 30% | nearly six times the revenue reported in the third quarter of 2025 |
| Collaboration revenue, three months ended September 30, 2026GAAP | $12.32M | – | – |
| Grant revenue, three months ended September 30, 2026GAAP | $346K | – | – |
| Total revenue, three months ended September 30, 2026GAAP | $12.67M | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $71.89M | – | – |
| Acquired in-process research and development expense, three months ended September 30, 2026GAAP | $11.68M | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | $17.87M | – | – |
| Collaboration expense, net, three months ended September 30, 2026GAAP | $41.28M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $142.7M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$130.0M | – | – |
| Total other income, net, three months ended September 30, 2026GAAP | $18.68M | – | – |
| Net loss before income taxes, three months ended September 30, 2026GAAP | −$111.4M | – | – |
| Provision for income taxes, three months ended September 30, 2026GAAP | −$74K | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$111.4M | – | – |
| Foreign currency translation adjustment, three months ended September 30, 2026GAAP | $2K | – | – |
| Unrealized loss on marketable securities, three months ended September 30, 2026GAAP | −$9.46M | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$120.9M | – | – |
| Net loss per common share, basic, three months ended September 30, 2026GAAP | $(1.15) | – | – |
| Basic weighted-average common shares outstanding, three months ended September 30, 2026GAAP | 96,741,070 | – | – |
| Net loss per common share, diluted, three months ended September 30, 2026GAAP | $(1.15) | – | – |
| Diluted weighted-average common shares outstanding, three months ended September 30, 2026GAAP | 96,741,070 | – | – |
| Collaboration revenue, nine months ended September 30, 2026GAAP | $23.32M | – | – |
| Grant revenue, nine months ended September 30, 2026GAAP | $985K | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | $24.31M | – | – |
| Research and development expense, nine months ended September 30, 2026GAAP | $207.6M | – | – |
| Acquired in-process research and development expense, nine months ended September 30, 2026GAAP | $14.15M | – | – |
| General and administrative expense, nine months ended September 30, 2026GAAP | $52.60M | – | – |
| Collaboration expense, net, nine months ended September 30, 2026GAAP | $127.5M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $401.9M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$377.6M | – | – |
| Total other income, net, nine months ended September 30, 2026GAAP | $53.91M | – | – |
| Net loss before income taxes, nine months ended September 30, 2026GAAP | −$323.6M | – | – |
| Provision for income taxes, nine months ended September 30, 2026GAAP | −$1.87M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$325.5M | – | – |
| Foreign currency translation adjustment, nine months ended September 30, 2026GAAP | −$20K | – | – |
| Unrealized loss on marketable securities, nine months ended September 30, 2026GAAP | −$18.88M | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$344.4M | – | – |
| Net loss per common share, basic, nine months ended September 30, 2026GAAP | $(3.38) | – | – |
| Basic weighted-average common shares outstanding, nine months ended September 30, 2026GAAP | 96,437,995 | – | – |
| Net loss per common share, diluted, nine months ended September 30, 2026GAAP | $(3.38) | – | – |
| Diluted weighted-average common shares outstanding, nine months ended September 30, 2026GAAP | 96,437,995 | – | – |
| Cash, cash equivalents, and marketable securities, as of September 30, 2026GAAP | $2.28B | – | – |
| Cash and cash equivalents, as of September 30, 2026GAAP | $192.0M | – | – |
| Marketable securities, as of September 30, 2026GAAP | $2.08B | – | – |
| Marketable securities - non-current, as of September 30, 2026GAAP | $4.02M | – | – |
| Working capital, as of September 30, 2026GAAP | $2.14B | – | – |
| Total assets, as of September 30, 2026GAAP | $2.56B | – | – |
| Total shareholders' equity, as of September 30, 2026GAAP | $1.65B | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| CASGEVYMore than 750 patients have initiated treatment worldwide, and availability expanded for younger patients through approvals in the U.S., Saudi Arabia, the United Arab Emirates, Bahrain, and the U.K. | $99M | 30% | nearly six times the revenue reported in the third quarter of 2025 |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- CASGEVY generated $99 million of third-quarter 2026 revenue, representing 30% growth quarter-over-quarter.
- Collaboration expense, net, declined to $41.3 million from $57.1 million, primarily attributable to an increase in the Company's share of CASGEVY revenue.
- Research and development expense increased primarily because of higher external research and development expenses and sublicense fees, partly offset by lower employee-related costs.
- Acquired in-process R&D expense primarily consisted of a development milestone under the Sirius Agreement recognized in the third quarter of 2026.
- The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C.
- CRISPR Therapeutics completed enrollment in the Phase 2 CTX611 trial in patients undergoing total knee arthroplasty.
Concerns
- Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $106.4 million for the third quarter of 2025.
- Total operating expenses were $142,714 for the third quarter of 2026, compared to $132,948 for the third quarter of 2025.
- Research and development expense was $71.9 million for the third quarter of 2026, compared to $58.9 million for the third quarter of 2025.
- The company provided no financial guidance in the filing.
- The filing states that there is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.
What to watch
- Phase 1b CTX310 data in patients with severe hypertriglyceridemia at the American Heart Association Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT.
- Phase 1 zugo-cel data in patients with refractory systemic sclerosis at ACR Convergence 2026 on November 8 at 10:30 a.m. ET.
- An update from the Phase 2 CTX611 trial is expected in the second half of 2026.
- Updates from the Phase 1/2 zugo-cel trial in B-cell malignancies are anticipated in the second half of 2026.
- Further expansion of CASGEVY access, including uptake among younger pediatric patients following recent approvals.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025.
- The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.
- Working capital was $2,144,117 as of September 30, 2026, compared to $1,836,551 as of December 31, 2025.
- Total assets were $2,556,412 as of September 30, 2026, compared to $2,265,243 as of December 31, 2025.
- Total shareholders' equity was $1,648,068 as of September 30, 2026, compared to $1,921,813 as of December 31, 2025.
Analysis
The quarter centered on CASGEVY commercialization. CASGEVY generated $99 million of third-quarter 2026 revenue, up 30% quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025. The company stated that more than 750 patients have initiated treatment worldwide and that patient availability expanded through approvals for younger children in several markets. The reported collaboration revenue in the consolidated statement of operations was $12,323 for the quarter, compared with $— in the prior-year quarter.
The consolidated income statement remained loss-making. Total revenue was $12,669 for the three months ended September 30, 2026, compared with $889 in the prior-year period, while total operating expenses rose to $142,714 from $132,948. Research and development expense increased to $71,888 from $58,902, and the company recorded $11,675 of acquired in-process research and development expense related primarily to a Sirius Agreement development milestone. Collaboration expense, net, declined to $41,284 from $57,115, which management attributed to an increase in the Company's share of CASGEVY revenue. Net loss was $(111,437), compared with $(106,441).
For the first nine months, total revenue was $24,308 versus $2,646, while total operating expenses were $401,870 versus $512,453. The nine-month net loss was $(325,522), compared with $(450,986). The year-to-date reduction in operating loss reflected substantially lower acquired in-process R&D expense, which was $14,148 compared with $96,253 in the corresponding 2025 period, and lower collaboration expense, net, partly offset by higher R&D expense.
Liquidity increased following financing activity. Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared with $1,975.8 million as of December 31, 2025. The company attributed the increase primarily to net proceeds of $585.4 million from convertible senior notes issued in March 2026, offset by operating expenses. Total shareholders' equity was $1,648,068 as of September 30, 2026, compared with $1,921,813 as of December 31, 2025.
Pipeline execution supplied the other major developments. The FDA granted RMAT designations to CTX310 in severe hypertriglyceridemia and elevated LDL-C, the company completed enrollment in the Phase 2 CTX611 total knee arthroplasty trial, and upcoming disclosures include CTX310 Phase 1b data on November 9, 2026 and zugo-cel systemic sclerosis data on November 8, 2026. The filing did not provide financial guidance, cash runway guidance, capital-return activity, or operating and free cash flow figures.
Management, verbatim
The third quarter marked meaningful progress for CRISPR Therapeutics.
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics
CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease.
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics
With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics
Not in the filing
stated, not guessed- Financial guidance
- Prior outlook for comparison
- Gross margin
- Operating cash flow
- Free cash flow
- Cash runway guidance
- Debt balance as of September 30, 2026
- Share repurchases
- Dividend information
- Non-GAAP financial measures
- Prior-quarter values for consolidated statement of operations metrics
- Percentage year-over-year changes for consolidated statement of operations metrics
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is a standard 8‑K earnings release for CRISPR Therapeutics, a Nasdaq‑listed gene‑editing company.
Ticker impact
CRISPR Therapeutics reported Q3 2026 revenue of $99 million, a 30% QoQ increase and new FDA RMAT designations for CTX310.
likely upward pressure as investors price in higher revenue and FDA designations
Strong revenue growth, six‑fold year‑over‑year increase, and first‑in‑class FDA designations are material catalysts for a biotech stock.
Market effects
Boosts sentiment for gene‑editing and RNA‑based therapeutics sector.
Positive for US biotech market and European partners with approvals.
Highlights growing acceptance of CRISPR therapies worldwide.
Counterpoint
Revenue still modest; upcoming trial data may be delayed, limiting near‑term upside.
Key entities
- companyCRISPR Therapeutics AG
Nasdaq‑listed biotech developing CRISPR‑based therapies.
- regulatorFDA
Granted Regenerative Medicine Advanced Therapy designations to CTX310.
